Miriam Banoub Morkos

Dr. Miriam Banoub Morkos

Department of Pharmacy Practice, Marshall B. Ketchum University, Fullerton, California, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2017 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
XCXu Chen
Xu Chen
WZWensheng Zhang
Wensheng Zhang
SRSandy Rios
Sandy Rios
Miriam Banoub MorkosMiriam Banoub Morkos
Miriam Banoub Morkos
XYXiaoli Ye
Xiaoli Ye
LWLing Wang
Ling Wang

29 September 2024 in Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
Miriam Banoub MorkosMiriam Banoub Morkos
Miriam Banoub Morkos
GLGiovani Leon
Giovani Leon
MHMai-Chi Hong
Mai-Chi Hong
JGJoshua Allan Garcia
Joshua Allan Garcia
MBMartin J. Breen
Martin J. Breen
Lee NguyenLee Nguyen
Lee Nguyen
Dalbavancin, a semi-synthetic lipoglycopeptide with an extended half-life that allows for weekly dosing, is currently approved for the treatment of bacterial skin and soft tissue infections caused by susceptible gram-positive organisms. This case report discusses the successful treatment of septic arthritis with dalbavancin in a 38-year-old obese male. Septic arthritis, commonly caused by Staphylococcus aureus and Streptococcus species, was diagnosed in this patient following a mechanical fall that led to worsening shoulder pain. Given the patient’s morbid obesity and concerns about antibiotic penetration, dalbavancin 1500 mg IV biweekly was chosen for its extended half-life and ease of administration. This case underscores dalbavancin’s efficacy in managing septic arthritis in obese patients, offering a convenient alternative to traditional therapies that require a peripherally inserted central catheter (PICC line), frequent dosing, therapeutic monitoring, and prolonged hospital stays. Despite its higher cost, dalbavancin’s advantages include reduced need for PICC lines, additional staff and resources to monitor therapeutic drug levels, and fewer complications, which can offset some expenses. To our knowledge, this is the first documented case investigating the use of dalbavancin for enterococcal septic arthritis with a biweekly dosing regimen.